<DOC>
	<DOCNO>NCT02175394</DOCNO>
	<brief_summary>The objective investigate effect multiple oral dos 5 mg BI 1356 steady-state pharmacokinetics ethinylestradiol ( EE ) levonorgestrel ( LNG ) , component MicrogynonÂ®</brief_summary>
	<brief_title>Effect Multiple BI 1356 Doses Multiple-dose Pharmacokinetics Combination Ethinylestradiol Levonorgestrel Healthy Female Premenopausal Subjects</brief_title>
	<detailed_description />
	<mesh_term>Levonorgestrel</mesh_term>
	<mesh_term>Ethinyl estradiol , levonorgestrel drug combination</mesh_term>
	<mesh_term>Ethinyl Estradiol-Norgestrel Combination</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<criteria>Healthy premenopausal female subject determine result screen base upon complete medical history , include physical examination , vital sign ( blood pressure ( BP ) , heart rate ( HR ) ) , 12lead electrocardiogram ( ECG ) , clinical laboratory test Age 18 40 year BMI 18.5 27 kg/m2 ( Body Mass Index ) Signed date write informed consent prior admission study accordance Good Clinical Practice ( GCP ) local legislation Gynaecological examination without relevant finding Any find medical examination deviate normal clinical relevance . Systolic blood pressure great 140 mm Hg diastolic blood pressure great 90 mm Hg Any evidence clinically relevant concomitant disease Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder Surgery gastrointestinal tract ( except appendectomy ) Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder History relevant orthostatic hypotension , faint spell blackouts Chronic relevant acute infection History relevant allergy hypersensitivity ( include allergy drug excipients ) Intake drug long halflife ( great 24 hour ) within least one month le 10 halflives respective drug prior day 1 trial Use antibiotic drug know inhibit induce cytochrome P450 enzymes , especially CYP3A4 , within one month prior study day 1 trial ( CYP3A4 inhibitor example azole antimycotic , macrolides , CYP3A inducers example St. John 's Wort certain anticonvulsant ) Participation another trial investigational drug within two month prior day 1 trial Regular smoker two cigarette daily Drug alcohol abuse ( 20 g alcohol/day ) Blood donation ( 100 mL within four week prior day 1 ) Excessive physical activity within 48 hour prior day 1 ) Any laboratory value outside reference range clinical relevance Inability comply dietary regimen trial site Positive pregnancy test , pregnancy plan become pregnant within 2 month study completion , lactation No use additional contraceptive method 6 week last study drug administration , i.e . barrier method , sexual abstinence , nonhormonecontaining intrauterine device ( IUD ) , surgical sterilisation ( incl . hysterectomy ) vasectomize partner Use oral contraceptivecontaining intrauterine device , depot injection contraceptive implant Existing history confirm venous thromboembolism ( VTE ) , family history idiopathic VTE know risk factor VTE . Existing previous arterial thrombotic embolic process , condition predispose e.g . disorder clot process , valvular heart disease atrial fibrillation Relevant varicosis History migraine History liver disease , i.e . disturbance liver function , jaundice persistent itch previous pregnancy , DubinJohnson syndrome , Rotor syndrome , previous exist liver tumour Clinically relevant cycle anomaly dysmenorrhoea within last 12 month Usual menstrual cycle duration outside 2632 day range</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>